2 Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, Peoples Republic of China *These authors contributed equally to this work Correspondence: Ligang Zhou Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, Peoples Republic of China Tel +8613611927616 Email [email protected] Abstract: GLP-1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors (SGLT-2is) are novel antidiabetic medications associated with considerable cardiovascular benefits therapying treatment of diabetic patients
Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
et al (2021)
By early 2026, FDA had publicly announced enforcement actions against multiple compounded GLP-1 telehealth platforms, and in April 2026 formally proposed removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list - with a public comment period running through June 2026
Healthcare providers have been prescribing semaglutides or GLP-1 drugs for diabetes treatment and as weight management
